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Abstract
We demonstrate that tissue plasminogen activator (tPA) and its inhibitors contribute to neurite outgrowth in the
central nervous system (CNS) after treatment of stroke with multipotent mesenchymal stromal cells (MSCs). In vivo,
administration of MSCs to mice subjected to middle cerebral artery occlusion (MCAo) significantly increased activation
of tPA and downregulated PAI-1 levels in the ischemic boundary zone (IBZ) compared with control PBS treated mice,
concurrently with increases of myelinated axons and synaptophysin. In vitro, MSCs significantly increased tPA levels
and concomitantly reduced plasminogen activator inhibitor 1 (PAI-1) expression in astrocytes under normal and
oxygen and glucose deprivation (OGD) conditions. ELISA analysis of conditioned medium revealed that MSCs
stimulated astrocytes to secrete tPA. When primary cortical neurons were cultured in the conditioned medium from
MSC co-cultured astrocytes, these neurons exhibited a significant increase in neurite outgrowth compared to
conditioned medium from astrocytes alone. Blockage of tPA with a neutralizing antibody or knock-down of tPA with
siRNA significantly attenuated the effect of the conditioned medium on neurite outgrowth. Addition of recombinant
human tPA into cortical neuronal cultures also substantially enhanced neurite outgrowth. Collectively, these in vivo
and in vitro data suggest that the MSC mediated increased activation of tPA in astrocytes promotes neurite outgrowth
after stroke.
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Introduction
Cultured medium from multipotent mesenchymal stromal cells
(MSCs) increases neurite outgrowth in cultured neurons [1], and
MSC treatment of stroke enhances functional recovery and
increases neurite outgrowth in rodents [2,3]. MSCs secrete and
stimulate parenchymal cell production of bioreactive factors in
brain after stroke [4–7]. We therefore sought to identify the
key restorative factors that promote MSC stimulated neurite
outgrowth.
The plasminogen activator (PA)/plasmin system is a major
proteolytic system in the adult central nervous system (CNS)
[8–11]. With specific inhibitors, i.e., plasminogen activator
inhibitor (PAI)-1 (encoded by serpine 1 gene, secreted by
neurons and active astrocytes) and neuroserpin (encoded by
serpini 1 gene, secreted by neurons) [12–14], the activity of the
PA/plasmin system is in equilibrium in the mammalian brain.
The PA/plasmin system and its inhibitors participate in a
number of physiological and pathological events in the CNS
[15–17], and facilitate neurite outgrowth and sustain synaptic
plasticity via interaction with extracellular matrix proteoglycans
[18–20].
In brain, tissue plasminogen activator (tPA) expression in
astrocytes is the primary source of plasminogen activator and PAI-
1 is the dominant inhibitor of tPA [21]. Gene array analysis of
primary astrocyte cultures derived from wild-type (WT) and glial
fibrillary acidic protein (GFAP)/vimentin (Vim) double knock-out
mice reveal that only the PAI-1 gene, out of 1200 genes measured
was downregulated by threefold or higher in the knock-out
animals [22]. MSCs modify ischemia-induced astrocytic activation
and reduce GFAP expression in astrocytes in vitro [23] and
significantly reduce the thickness of the scar wall in vivo [3,24].
Therefore, we hypothesize that MSCs decrease PAI-1 expression
and stimulate tPA after ischemia and thereby promote neurite
remodeling.
In this study, we measured tPA/PAI-1 expression and tPA
activity in astrocytes cultured under normal and oxygen and
glucose deprivation (OGD) conditions and co-cultured with or
without MSCs as an in vitro ischemia model. To test the effects of
tPA/PAI-1 in astrocytes on neurite outgrowth, conditioned media
from cultured astrocytes were added to primary cultured cortical
neurons. In addition, mice subjected to middle cerebral artery
occlusion (MCAo) were employed to test for tPA activity and
neurite outgrowth in vivo.
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MSC Co-Culture Alters tPA and PAI-1 Expression in
Normal and OGD Astrocytes
qRT-PCR was employed to measure tPA and PAI-1 mRNA in
cultured astrocytes responding to OGD and MSC co-culture.
Fig. 1a, b shows that normal cultured astrocytes express tPA and
PAI-1 mRNA. tPA and PAI-1 mRNA levels were significantly
increased in astrocytes subjected to OGD compared to normal
astrocytes, respectively. MSC co-culture significantly increased the
tPA mRNA levels in both normal and OGD astrocytes, whereas
MSCs significantly decreased the PAI-1 mRNA level in OGD
astrocytes (1b) compared to normal and OGD astrocytes without
MSC co-culture, respectively.
Western blot was employed to measure the tPA and PAI-1
protein levels in cultured astrocytes in response to OGD and MSC
co-culture (Fig. 1c, d). OGD treatment significantly increased tPA
and slightly increased PAI-1 protein levels in astrocytes. MSC co-
culture significantly increased tPA and decreased the PAI-1
protein levels in normal and OGD astrocytes compared to normal
and OGD astrocytes without MSC co-culture, respectively (1d).
MSC Co-Culture Alters tPA Level and Activity in
Conditioned Medium
When tPA is bound with PAI-1 or its other inhibitors, tPA is
inactive [25]; conversely, tPA is active when unbound. Active
mouse tPA binds to the biotinylated human PAI-1 coated on a
microtiter, and an ELISA kit can be used to measure the active
tPA in conditioned media. The total tPA protein and active tPA in
various conditioned media were measured with ELISA kits
(Table 1). Normal cultured astrocytes secreted tPA at a
concentration of 1.2760.02 ng/mL, and normal astrocytes co-
cultured with MSCs significantly (p,0.05) increased the tPA
concentration to 1.3260.01 ng/mL. In OGD astrocytes, MSC co-
culture increased the tPA concentration to 2.2460.08 ng/mL
compared to OGD astrocytes without MSC co-culture
(2.1460.14 ng/mL). tPA concentrations were significantly in-
creased in OGD astrocytes with or without MSC co-culture
compared with normal cultured astrocytes (p,0.01), respectively.
The active tPA concentration in normal cultured astrocyte
medium was 0.3160.01 ng/mL, and MSCs significantly increased
the active tPA concentration in normal astrocytes to 0.496
0.02 ng/mL. MSC co-culture significantly increased the active
tPA concentration to 0.3660.02 ng/mL in OGD astrocytes
compared with OGD astrocytes without MSC co-culture (0.246
0.03 ng/mL).
Only active tPA can perform proteolytic function; we there-
fore used the direct casein zymography assay to visualize and
measure tPA activity in cultured astrocytes and conditioned
media under normal and OGD conditions and to determine
whether tPA activity is modified by MSC co-culture. Fig. 2a, 2b
Figure 1. tPA and PAI-1 mRNA and protein levels in treated
astrocytes. qRT-PCR shows mRNA levels of tPA and PAI-1 in normal
cultured astrocytes (A), astrocytes co-cultured with MSCs (A-M), OGD
astrocytes (AO) and OGD astrocytes co-cultured with MSCs (AO-M) (a).
OGD treatment significantly increased tPA and PAI mRNA levels in
astrocytes. MSC co-culture significantly increased tPA mRNA level in
both normal and OGD astrocytes whereas MSC co-culture significantly
decreased PAI-1 mRNA level (b) in OGD astrocytes. Western blot shows
protein levels of tPA and PAI-1 in normal cultured astrocytes (A),
astrocytes co-cultured with MSCs (A-M), OGD astrocytes (AO) and OGD
astrocytes co-cultured with MSCs (AO-M) (c). OGD treatment increased
tPA and PAI protein level and co-culture MSCs increased tPA protein
level whereas MSCs decreased PAI-1 protein level (d). *P,0.05,
**P,0.01, compared with group A; ++P,0.01, compared with group
AO.
doi:10.1371/journal.pone.0009027.g001
Table 1. Total tPA protein and active tPA concentration in
various conditioned media (n=6/group).
Groups
Total tPA concen-
tration (ng/mL)
Active tPA concen-
tration (ng/mL)
A 1.2760.02 0.3160.01
A-M 1.3260.01* 0.4960.02**
AO 2.1460.14** 0.2460.03*
AO-M 2.2460.08** 0.3660.02
##
A: medium from normal cultured astrocytes; A-M: medium from normal
astrocytes co-cultured with MSCs; AO: medium from OGD astrocytes; AO-M:
medium from OGD astrocytes co-cultured with MSCs.
*P,0.05.
**P,0.01 compared with group A.
##P,0.01 compared with group AO.
doi:10.1371/journal.pone.0009027.t001
Figure 2. tPA activity of astrocyte lysates and conditional
media. Zymography (a, b) shows that MSCs significantly increased tPA
activity in normal cultured astrocytes and in OGD treated astrocytes (c),
and similar results were obtained using the conditioned media
harvested from the concomitant groups (d). Marker: prestained protein
marker; A: normal cultured astrocytes; A-M: normal astrocytes co-
cultured with MSCs; AO: OGD astrocytes; AO-M: OGD astrocytes co-
cultured with MSCs. *P,0.05, **P,0.01, compared with group A;
##P,0.01, compared with group AO.
doi:10.1371/journal.pone.0009027.g002
MSCs Regulate tPA Activity
PLoS ONE | www.plosone.org 2 February 2010 | Volume 5 | Issue 2 | e9027show that OGD treatment significantly decreased the tPA
activity in astrocytes. MSCs significantly increased this ac-
tivity both in normal astrocytes and in OGD treated astro-
cytes. Similar results were obtained in the conditioned media
harvested from the concomitant groups of cultured astrocytes
(Fig. 2c, 2d).
MSCs Increase Neurite Outgrowth of Cortical Neurons via
Activated tPA
To test whether tPA in conditioned media affects neurite
outgrowth, a primary culture cortical neuronal system was used.
Primary cultured cortical neurons were treated with various
conditioned media for 4 days. A tPA neutralizing antibody was
used to reduce the effects of tPA, and rh-tPA was used as a positive
control. The normal control group was cultured with neurobasal
culture medium.
Fig. 3a shows the typical morphology of cultured neurons
treated with conditioned media. rh-tPA treatment significantly
increased the neurite branch number and total neurite length of
cultured neurons. Compared to neurobasal medium cultured
neurons, the neurite branch number and total length were
significantly increased when treated with the normal cultured
astrocyte conditioned medium. The OGD astrocyte medium
significantly decreased neurite branch number and total length.
Co-culture with MSCs significantly increased neurite branch
number and total length both of neurons cultured with normal
cultured astrocyte medium and with OGD astrocyte medium,
respectively. The tPA neutralizing antibody sharply counteract-
ed the effects of MSC co-culture media on neurite number and
total length, and neurite branch number and length were
significantly reduced compared with normal control group
(Fig. 3b, 3c). To verify the neurite outgrowth promoting effect of
tPA secreted by astrocytes, the siRNA technique was used to
knock-down the tPA expression in astrocytes. Fig. 3d shows the
tPA level was substantially down regulated by transfecting
astrocytes with tPA siRNA. Medium from tPA knock-down
astrocytes significantly reduced the neurite number and total
length of cultured neurons compared with medium from normal
astrocytes or negative control siRNA transfected astrocytes
(Fig. 3b, 3c).
Figure 3. Neurite outgrowth in primary cultured cortical neuron after conditional media treatment. Fluorescence microscopy (a) shows
cortical neurite outgrowth. Control: primary cultured cortical neurons with neurobasal medium; medium from normal cultured astrocytes (A)
increased neurite number and total length compared to those in control group; medium from OGD astrocytes (AO) significantly decreased neurite
number and total length; media from normal astrocytes co-cultured with MSCs (A-M) and OGD astrocytes co-cultured with MSCs (AO-M) increased
neurite total length compared to that in A and AO groups, respectively, and increased neurite number in AO-M group compared with AO group. tPA
neutralizing antibody specifically antagonized tPA effects of AM and AO-M groups in neurite number and total length (b, c). Western blot shows that
tPA expression in astrocytes was substantially down regulated by tPA siRNA (d). Medium from tPA knock-down astrocytes significantly reduced the
neurite number and total length of cultured neurons compared with that from normal astrocytes or negative control siRNA transfected astrocytes (b,
c). A-MT: medium from normal astrocytes co-cultured with MSCs, t-PA neutralizing antibody presented; AO-MT: medium from OGD astrocytes co-
cultured with MSCs, t-PA neutralizing antibody presented; t-PA: 15nM rh-t-PA alone; AC: medium from astrocytes transfected with negative control
siRNA; AS: medium from astrocytes transfected with tPA siRNA. Scale bars=50 mm. *P,0.05, ** P,0.01, compared with control group; #P,0.05,
##P,0.01, compared with A group; ++P,0.01, compared with A-M group;
‘‘P,0.01, compared with AO group; {{P,0.01, compared with AO-M
group; &&P,0.01, compared with AC group. Data are presented as Mean6SE, (neurons n=50/group, Adjusted p-value=0.0042).
doi:10.1371/journal.pone.0009027.g003
MSCs Regulate tPA Activity
PLoS ONE | www.plosone.org 3 February 2010 | Volume 5 | Issue 2 | e9027Endogenous tPA Expression Level and Activity in Mouse
Brain after Stroke with and without MSC Treatment
Stroke significantly increased expression of tPA and PAI-1 in
the ischemic hemisphere compared to non-ischemic brain (Fig. 4a,
4b). Treatment of stroke with MSCs significantly increased tPA
expression and decreased PAI-1 expression compared with PBS
treatment. tPA activity in the MCAo control brain extract and in
the MCAo MSC treated brain extract was measured using
zymography. Fig. 4c, 4d show that MSC treatment significantly
increased the activity of tPA compared to MCAo alone mice at 14
days after stroke.
tPA and PAI-1 mRNA Levels in Astrocytes Located within
the Ischemic Boundary Zone (IBZ) Respond to MSCs
We employed laser capture microdissection (LCM) combined
with RT-PCR to measure tPA and PAI-1 mRNA levels in
astrocytes in the IBZ (Fig. 5a) after stroke with or without MSC
treatment. Fig. 5b shows that MSC treatment significantly
increased the tPA mRNA level and concomitantly decreased the
PAI-1 mRNA level. These data indicate that astrocytes in the IBZ
respond to MSC treatment and increase tPA and concomitantly
decrease PAI-1 gene expression.
MSC Treatment Increases Axonal Fiber and Synaptic
Regeneration in the IBZ
Double staining of Bielshowsky silver and Luxol fast blue can
identify axonal fibers and myelin, respectively, in the white matter
of the brain [26]. The ischemic attack severely damaged white
matter bundles in the core lesion area and axon-myelin bundles
were altered and appeared disorganized in the IBZ (top-left in
Fig. 6b, 6c) of the striatum compared to normal mice (Fig. 6a).
Axonal fiber density in the IBZ of the striatum was significantly
increased after MSC treatment (Fig. 6c, 6d) compared with MCAo
control animals (Fig. 6b, 6d).
Synaptophysin is an indicator of presynaptic plasticity and
synaptogenesis [27]. Stroke decreased synaptophysin expression in
the IBZ of the striatum (Fig. 6f) compared to the normal mice
(Fig. 6e). MSC treatment significantly increased synaptophysin
expression (Fig. 6g, 6h) compared with MCAo control mice
(Fig. 6f, 6h), suggesting that MSC treatment increases synaptic
regeneration after MCAo.
To identify the effects of MSCs on neuronal apoptosis, we
performed double staining with TUNEL and MAP 2. At 14 days
after stroke, only few scattered apoptotic neurons were evident,
and MSCs decreased the number of apoptotic neurons compared
to MCAo control animals (Fig. 6i–6l). These data suggest that,
although we cannot exclude a contribution of MSC induced
neuroprotection to the MSC mediated increase in axonal fiber
density and synaptophysin expression, the reduction in apoptosis
likely plays a minor role in the observed white matter remodeling.
Discussion
MSCs are localized to the boundary region of the ischemic
infarct in rodents [28–32], MSCs improve recovery from stroke in
mice and rats directly by secreting soluble factors [5,6] and
indirectly by stimulating parenchymal cells of the stroke brain to
secrete bioactive factors [4,7,33–37], which induce neurogenesis,
angiogenesis, white matter change, synaptogenesis and reduce
apoptosis [4,7,38–41]. In this study, we show for the first time that
MSCs also enhance neurite outgrowth, which benefits brain
recovery after stroke, by concomitantly decreasing the expression
of the tPA inhibitor PAI-1 and increasing the activity of tPA in
astrocytes in the peri-infarct area of ischemic brain. Thus, the
modulation of tPA activity by MSCs likely promotes neurite
remodeling and thereby may improve functional outcome after
stroke.
tPA, which influences neurite outgrowth, is expressed by many
types of neural cells in the developing brain, including astrocytes
Figure 4. tPA and PAI-1 levels and tPA activity in mice
subjected to MCAo with or without MSC treatment. Western
blot shows tPA protein level (a) and zymography shows tPA activity (b)
in MCAo mice with or without MSC treatment. tPA and PAI-1 expression
was significantly increased in the IBZ of mice subjected to MCAo
compared with normal mice. tPA expression was significantly increased
and PAI-1 expression was significantly decreased in the IBZ of MCAo
mice after MSC treatment compared with MCAo alone mice (c). MSC
treatment significantly increased the activity of tPA in the IBZ compared
with MCAo alone mice (d). N: normal mouse brain tissue; C: IBZ tissue
from MCAo mice; M: IBZ tissue from MCAo mice after MSC treatment.
**P,0.01, compared with normal mice; #P,0.05, ##P,0.01, com-
pared with control MCAo mice.
doi:10.1371/journal.pone.0009027.g004
Figure 5. tPA and PAI-1 level in MCAo mouse IBZ astrocytes
respond to MSC. (5a) presents the individual IBZ astrocytes dissected
using LCM (before and after dissection), and tPA and PAI-1 mRNA level
in these astrocytes with or without MSC treatment are shown in (b).
MSC treatment significantly increased tPA mRNA level and concomi-
tantly decreased PAI-1 mRNA level. Scale bars=50 mm. *P,0.05
compared with MCAo mice.
doi:10.1371/journal.pone.0009027.g005
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against tPA significantly reduced neurite outgrowth and branch
numbers compared to control neurons without tPA treatment.
Using LCM, we have demonstrated that astrocytes in the IBZ
respond to MSC treatment by increasing tPA activity (i.e. increase
of tPA level with a concomitant decrease of PAI-1 level). We do
not exclude a contribution from other parenchymal cells to the
MSC enhanced tPA activity; however, the high concentration of
astrocytes in the IBZ and the predominance of numbers astrocytes
in parenchymal tissue, suggest that the astrocyte is a robust
contributor to the MSC mediated tPA activity and subsequent
functional recovery. This is the first study to suggest that tPA
activity enhanced by astrocytes contributes to the therapeutic
benefits of a cell-based therapy.
Extracellular matrix (ECM) degradation is needed for neurite
outgrowth and the remodeling of crossing axonal fibers [18]. The
plasmin system plays an active role in tissue remodeling. Plasmin
degrades the ECM, directly by removing glycoproteins from the
ECM [43] and it releases axonal guidance molecules from the
extracellular matrix [19]. tPA has multifaceted effects on tissue; it
interacts with parenchymal cells through proteolytic plasminogen
or non-plasminogen pathways [44–47]. The proteolytic plasmin-
ogen/plasmin function of tPA cleaves the precursor forms of
neurotrophins to the active forms of these trophic factors, e.g.
proteolytic activity by tPA converts proBDNF and proNGF in the
ECM to active trophic factors, respectively [48–50]. These trophic
factors promote neurite remodeling [51–55]. The plasmin
dependent pathway has multiple roles in addition to the cleavage
of pro-neurotrophins into the active form [56]. Plasmin also
activates the N-methyl-D-Aspartate receptor (NMDAR) which can
subsequently enhance neurite remodeling [57]. Moreover, recent
studies report that the NMDAR can act independently of the
plasminogen pathway and stimulate nitric oxide synthase (NOS),
which increases nitric oxide (NO) and subsequently increases
cyclic guanosine monophosphate (cGMP) which can foster neurite
remodeling [58]. Similarly, the low-density lipoprotein receptor
pathway (LDLR), has been shown to mediate enhancement of
NMDAR function by tPA [59]. In addition to the PA/plasmin
system, tPA interacts with other effectors such as low-density
lipoprotein receptor-related protein (LRP) [60,61] and latent
platelet-derived growth factor-CC (PDGF-CC) [62,63] which may
subsequently influence the brain ECM remodeling and neurite
outgrowth. tPA converts PDGF-CC to an active form PDGF-C,
which is expressed in embryonic and adult mouse brain and
contributes to brain remodeling and spinal cord development [64].
MSC treatment increases tPA activity in astrocytes and thereby
promotes white matter remodeling which likely contributes via
multiple pathways to recovery of neurological function after stroke.
As a member of the serpine gene family, PAI-1 is the major
inhibitor of tPA [21], and is largely produced by reactive
astrocytes in the CNS after stroke [65,66]. PAI-1 plays an
important role in the process of peripheral tissue remodeling and
fibrinolysis through inhibition of plasmin-dependent ECM degra-
dation [67]. Hypoxia and many growth factors, including
transforming growth factor beta (TGFb) and tumor necrosis
factor alpha (TNF-a), as well as other chemicals/agents, induce
PAI-1 expression in cultured cells and in vivo [68]. The con-
comitant MSC induced reduction of PAI-1 and increase of tPA
in astrocytes of the IBZ thereby amplify tPA activity which
contributes to neurite outgrowth.
Figure 6. MSCs promote neurite outgrowth, synaptic plasticity and cell survival. Double staining (Bielshowsky, black for axons, indicated
by green arrow; Luxol fast blue for myelin, indicated by red arrow.) shows axonal and myelin fibers in the striatum (b–c) along the IBZ after MCAo
compared to normal brain (a). The integrated density (indicated the axonal and myelin fibers number) of white matter bundles in IBZ of striatum was
decreased compared with that in normal brain, The axonal fibers and myelin of the striatum were enhanced by MSCs (c, d, Adjusted p-value=0.0167).
Immunofluorescent staining (e–g) shows synaptic regeneration (indicated by synaptophysin). Synaptophysin expression significantly increased in
MSC treated rats (g, h, Adjusted p-value=0.025). Apoptosis neuron (indicated by white arrow) is shown with double staining with TUNEL and MAP 2
(i–k), MSCs decreased the apoptosis neuron number (k, l, Adjusted p-value=0.01667). Scale bars=25 mm. **P,0.01, compared with normal mice;
##P,0.01, compared with control MCAo alone mice.
doi:10.1371/journal.pone.0009027.g006
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upregulated within the peri-infarct region of the brain early after
stroke [69]. tPA expression as well as its inhibitors PAI-1 and
neuroserpin are up-regulated in the acute stage of cerebral
ischemia and hemorrhage [13,70,71]. An increase of parenchymal
cell expression of tPA early after stroke may be a negative factor
for neural cell survival and for sustaining blood-brain barrier
(BBB) integrity. Elevated PAI-1 expression inhibits tPA activity
and reduces injury from stroke [72,73]. In addition to its damaging
role, the tPA/plasmin proteolytic system provides benefits by
facilitating neurite outgrowth and pathfinding [10,11]. Our in
vitro studies which mimic ischemic conditions show increased tPA
and PAI-1 expression in OGD astrocytes, and that MSC-astrocyte
co-culture concomitantly decreased the PAI-1 expression and
increased tPA activity in astrocytes. In vivo, treatment of MCAo
with MSCs increased tPA activity, and this increase likely
contributed to the observed neurite outgrowth and synaptic
plasticity. Our data provide a new insight, that MSC cell based
therapy for stroke promotes neurite outgrowth, axonal regenera-
tion and synaptic plasticity via the astrocytic tPA system.
The roles that reactive astrocytes take after brain injury
are multi varied [74–76]. Astrocytes promote or inhibit axonal
regeneration. The glial scar formed by the astrocyte has an initial
beneficial effect of walling off the lesion from the intact
parenchyma, likely protecting the intact tissue from the invading
macrophages and other potentially toxic events. Rapidly expand-
ing astrocytic processes create functional walls surrounding the
ischemic core, which extend the time available for marshalling
endogenous repair mechanisms, e.g., redirection of blood flow to
still salvageable parts of the brain and redirection of neurite
sprouting and synapse formation to build new circuitry [77]. The
glial scar, also produces inhibitory glycoproteins [78,79], which
reduce neurite outgrowth. Administration of MSCs to rodents
reduces the glial scar and also reduces the expression of inhibitory
glycoproteins, thereby creating a permissive environment for
neurite outgrowth [24,80]. The tPA/PAI-1 system associated
with the reactive astrocyte impacts ischemic damage and
regenerative events. Early after stroke, reactive astrocytes secrete
abundant factors, such as tPA as well as PAI-1 [24,81–83].
Increasing PAI-1 inhibits tPA activity and subsequently inhibits
the tissue damage within the ischemic area [84,85]. However,
during the sub-acute stage after stroke, our data support the
hypothesis that the tPA/PAI-1 system of the reactive astrocytes is
beneficial, increasing neurite outgrowth. MSCs reduce PAI-1 in
reactive astrocytes, which thereby increase tPA activity. This
enhanced tPA activity may increase active neurotrophins
[48–50,86]. The mechanisms by which MSCs increase PA
activity, await further investigation.
There are many factors that contribute to the improvement of
neurological function after MSC treatment of stroke [28,41,87–
91]. We propose that astrocytes contribute to the beneficial effects
of exogenously administered MSCs in the CNS. Although the
most abundant cells in the CNS, astrocytes have been neglected as
modulators of brain remodeling and functional recovery. The
tPA/PAI-1 system in astrocytes by promoting brain plasticity
leading to functional recovery after treatment of stroke with MSCs
may provide a new therapeutic target for stroke and CNS diseases.
Materials and Methods
All experimental procedures were carried out in accordance
with the NIH Guide for the Care and Use of Laboratory Animals
and approved by the Institutional Animal Care and Use
Committee of Henry Ford Hospital.
Cell Culture
The MSCs employed in our studies are very well characterized
and are provided to us by Theradigm, Inc. (Baltimore, MD) and
produced in a GMP facility. Briefly, the bone marrow harvested
from the hind legs of C57/Bl6 mice (2,3 m) were prepared, as
previously described [31,92–94]. The MSCs are a heterogeneous
cell population, and comply with three well established criteria;
they 1. are plastic-adherent, 2. express specific surface antigen
expression, and 3. in vitro can differentiate into osteoblasts,
adipocytes, and chondroblasts [95]. The mouse MSC populations
were analyzed for the following surface antigens for phenotypic
characterization: CD29 (.90%), CD44 (.80%) and CD105
(.80%) and were free of hematopoietic cell phenotype CD11b
(,1%), CD34 (,1%), and CD45 (,1%). MSCs were cultured
with a-modified MEM medium (Hyclone, Logan, UT) containing
20% fetal bovine serum (FBS, Gibco Laboratory, Grand Island,
NY) and penicillin-streptomycin on 75 cm
2 tissue culture flasks
(Corning St. Louis, MO). Mouse cortical astrocytes, C8-D1A
(Astrocyte type I clone from C57/BL6 strains), were obtained from
the American Type Culture Collection (ATCC, CRL-2541
TM,
Arlington, VA). Cells were cultured in high glucose Dulbecco’s
modified eagle medium (DMEM, Invitrogen, San Diego, CA) with
10% FBS, containing penicillin-streptomycin on 75 cm
2 tissue
culture flasks, and all the cells were placed in an moist incubator
and cultured at 37uC, with 5% CO2.
OGD Treatment of Astrocytes
Astrocytes (1610
5) were seeded in each well of a 6-well plate
containing normal medium. After cells grew to 70% confluence,
the medium was replaced with non-glucose culture media and
cultured in an anaerobic chamber (model 1025, Forma Scientific,
OH) for 2 hrs. The astrocytes were then cultured under normal
conditions with or without MSCs. For co-culture with MSCs, an
upper chamber of the transwell insert dish (Becton Dickinson
Labware, FALCONH) was used with a ratio 1:100 of co-cultured
MSCs to astrocytes. Astrocytes with or without MSC co-culture
were detached and collected for RNA and protein extraction after
24 hrs.
Preparation of Conditioned Media
To prepare the conditioned media for the primary cortical
neuronal culture, Gibco
TM Neurobasal
TM Medium (Invitrogen,
Cat No. 21103) supplemented with B27 (Invitrogen, Cat
No. 17504-044) and L-Glutamine-Penicillin-Streptomycin solu-
tion (Sigma-Aldrich, Cat No. G6784) were used as basal culture
media. Briefly, following 2 hrs of OGD and subsequently normal
culture conditions with or without MSCs co-cultured for 24hrs,
normal and OGD astrocytes, respectively, were rinsed with basal
culture media. These astrocytes were then cultured in the basal
culture media for an additional 12 hrs with MSCs omitted. Media
from the various treatment groups are referred to as conditioned
media. Conditioned media were filtered with a 0.22mm-pore filter
and stored in -80uC for further studies. The conditioned media
were harvested from the replaced fresh basal culture media;
therefore, the tPA activity in the conditioned media derive solely
from the cultured astrocytes.
To knock-down the tPA expression in astrocytes, siRNA
technique was employed. Following the protocol provided by the
company, tPA siRNA (M-048467-01-0005, Thermo Fisher
Scientific. Lafayette CO 80026) and negative control siRNA were
transfected into triple well cultured astrocytes seeded in six well
plates, respectively. Conditioned media from these astrocytes
as well as normal cultured astrocytes were made following the
MSCs Regulate tPA Activity
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were lysed and for Western blot analysis.
ELISA Detection of the Total tPA and Active tPA
A mouse tPA total antigen assay kit (Innovative research,
Catalog No. MTPAKT-TOT) and a mouse tPA activity assay kit
(Innovative research, Catalog No. MTPAKT) were used to detect
the total tPA protein and active tPA level in conditioned media,
respectively. Following the manufacturer’s assay procedures,
conditioned media from normal and OGD astrocytes with or
without MSC co-culture were added into the wells of ELISA
plates, as well as various diluted tPA standards. The primary
antibody and second antibody were sequentially added. The
reaction was quenched by the addition of 1M H2SO4, The
absorbance values were read at 450nm.
MCAo and Tissue Preparation
Adult male mice (C57/BL6 strains, 2 months old, weighing 25–
29g) were employed in our study. Briefly, mice were initially
anesthetized with 3.5% isoflurane and maintained with 1.0% to
2.0% isoflurane in 70% N2O and 30% O2 using a facemask. The
rectal temperature was controlled at 37uC with a feedback-
regulated water heating system. The right common carotid artery,
external carotid artery (ECA), and internal carotid artery (ICA)
were exposed. A length of 6-0 monofilament nylon suture (8.0–
9.0 mm), determined by the animal weight, with its tip rounded by
heating near a flame, was advanced from the ECA into the lumen
of the ICA until it blocked the origin of the MCA. At 1 day
post-ischemia, randomly selected mice (n=9) received MSC
transplantation.
ForMSC transplantation,micewere initially anesthetizedwith
3.5% Isoflurane and maintained with 1.5% Isoflurane in 70%
N2Oa n d3 0 %O 2 using a face mask. Approximately 1610
6
MSCs in 0.2 ml total fluid volume of phosphate-buffered saline
(PBS) were injected into a tail vein. Immunosuppressants were
not used in any animal. Mice injected with PBS alone were
employed as MCAo control (n=9). A third group of naive mice
without surgery and treatment was employed as normal controls
(n=9).
All animals were sacrificed under deep ketamine anesthesia at
14 days after MCAo, among which 9 mice (n=3 for normal
control, MCAo alone and with MSC treatment, respectively) were
employed for tissue protein extraction, which were used for
Western blot and direct casein zymography. The remaining 18
mice (n=6 for normal control, MCAo alone and with MSC
treatment, respectively) were perfused with 0.9% saline, and a
series of frozen brain coronal sections (8 mm) were obtained
for histochemistry staining and Laser Capture Microdissection
(LCM).
Protein and RNA Isolation
Brain tissues from mice (n=3/group) along the IBZ ipsilat-
eral to the injury were extracted. These brain tissues were
homogenized, and were used to isolate total RNA and protein
with TRIzol (Invitrogen, San Diego, CA), following a standard
protocol.
The astrocytes cultured under various conditions were harvest-
ed and rinsed with PBS, then lysed in the RIPA lysis buffer
containing proteinase inhibitor cocktail (Roche, Indianapolis, IN).
Protein concentrations were determined using the Bicinchoninic
Acid (BCA) protocol (Pierce, Rockford, IL), loaded on 10% Bis-
Tris Gels (Invitrogen, San Diego, CA), and then processed for
Western blotting.
LCM Isolation of Reactive Astrocytes in the IBZ
Cryostat sections stored at 280uC were immediately immersed
in acetone for 2 min fixation and air-dried for 30 sec. After a
brief rinse with 0.1% diethylpyrocarbonate treated phosphate-
buffered saline (PBS), sections were incubated with GFAP
antibody (Dako Z0334; Dako, Carpinteria, CA) at 1:50 dilution
for 5 min, rinsed with PBS twice, and then incubated with 1:100
dilution CY3-conjugated F(ab9)2 anti-rabbit IgG secondary
antibody for 5 min. rinsed with PBS twice and air-drying for
5 min, GFAP positive reactive astrocytes along the ischemic
boundary were cut using Leica LMD6000 system. All reaction
steps were performed in RNase-free solutions. Approximately
5,000 cells were dissected and collected in Eppendorf tubes
containing 100 mL of lysis buffer. The samples were stored in
280uC before RNA isolation.
Quantitative Real Time PCR (qRT-PCR)
qRT-PCR was performed with the isolated total RNA
transcribed into cDNA using poly-dT oligonucleotides following
the manufacturer’s instructions. Quantitative PCR for total
cDNAs was performed in the ABI PRISM 7000 Sequence
Detection System, using the standard protocols with the Quantitec
SYBY Green PCR Kit (Qiagen, Valencia, CA). The following
primers were purchased from Invitrogen: mouse tPA, forward:
CTGAGGTCACAGTCCAAGCA, reverse: ACAGATGCTGT-
GAGGTGCAG; mouse PAI-1, forward: GTCTTTCCGACCA-
AGAGCAG, reverse: ATCACTTGGCCCATGAAGAG; and
mouse GAPDH, forward GTCTACTGGTGTCTTCACCAC-
CAT, reverse: GTTGTCATATTTCTCGTGGTTCAC. GAP-
DH was used as an internal control for gene expression.
Western Blot Assay
The total protein was used for Western blot assay following the
standard Western blotting protocol (Molecular Clone, Edition II).
The concentrations of the primary antibodies employed were: tPA
(1:2000, Santa Cruz, sc-15346), PAI-1 (1:2000, Santa Cruz, sc-
8979), and beta actin (1:5000, Santa Cruz, sc-1616). Respective
horseradish peroxidase (HRP) labeled secondary antibodies were
applied and enhanced chemiluminescence (ECL) detection was
used according to the manufacturer’s instructions (Pierce, Rock-
ford, IL). The integrated density mean grey value of the band was
analyzed under ImageJ software and the corresponding relative
expression ratio was calculated.
Direct Casein Zymography for tPA Activity
Proteins from culture supernatant, cells and brain tissues were
separated by 10% SDS-PAGE and tPA activity was assayed by
zymography, as detailed previously [96]. Briefly, 10mg protein
samples or 30mL conditioned supernatant were mixed with the
sample loading buffer without b-ME, and heating was omitted.
The mixture of the lower gel (10% acrylamide) contained casein
(1 mg/ml, Sigma) and plasminogen (13 mg/ml, American Diag-
nostica, Greenwich, CT) as substrates for plasmin and PA,
respectively. The gel was then washed for 30 min with 2.5%
Triton X-100 to remove SDS and further washed for 10 min with
0.1 M Tris buffer, pH 8. The new Tris buffer was replaced and
the gel was incubated for 4 hrs at 37uC to allow caseinolysis occur.
On the darkly stained casein background, PA activity was
visualized as light bands resulting from casein degradation. To
verify loading variations, duplicate samples were used in gel
electrophoresis. After electrophoresis, the gel was stained with
Coomassie Blue R-250 and destained with 40% methanol as well
as 10% acetic acid.
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The cortices were dissected from 17–18 day embryos of C57/
BL6 mice and dissociated in Ca
2+-a n dM g
2+-f r e eH a n k sb a l a n c e
salt solution (HBSS) containing 0.125% trypsin for 30 min. Cells
were washed with DMEM containing 5% FBS, triturated in
DMEM/5% FBS and passed through the cell strainer (BD Falcon
REF 352350). The cell density was determined by a hemacytom-
eter and 2610
4 cells per well were plated on eight-well chamber
slides (Nalge Nunc International, Naperville, IL). The cells were
incubated at 37uCw i t h5 %C O 2 overnight and switched to the
serum-free Neurobasal medium with B27 supplement for 3 days,
and the medium was then changed to conditioned media.
Treatment groups include: 1) neural basal medium as control,
2) medium from normal cultured astrocytes, 3) medium from
normal cultured astrocytes co-cultured with MSCs, 4) medium
from normal cultured astrocytes co-cultured with MSCs and
200ng/mL tPA neutralizing antibody (Product No. 1188, Amer-
ican Diagnostica Inc., Stamford, CT) [97–99] was added, 5)
medium from OGD astrocytes, 6) medium from OGD astrocytes
co-cultured with MSCs, 7) medium from OGD astrocytes co-
cultured with MSCs and 200ng/mL tPA neutralizing antibody
was added, 8) 15nM rh-tPA (Genentech Inc., South San
Francisco, CA), 9) medium from astrocytes transfected with
negative control siRNA, and 10) medium from astrocytes
transfected with tPA siRNA.
Neurite Outgrowth Assay
After 4 days in culture, neural cells were fixed with 4%
paraformaldehyde and stained with immunofluorescence for beta-
tubulin (Tuj 1) identification. To analyze neurite outgrowth, TuJ1-
positive cells were digitized using a 206 objective (Zeiss) via the
MicroComputer Imaging Device (MCID) analysis system (Imag-
ing Research, St. Catharines, Ontario, Canada). Neurite out-
growth was quantified using a software program developed in our
laboratory that includes measurements of the number and length
of branches [100]. At least fifty TuJ1-positive cells, distributed in 9
random fields per well and triple wells per group, were measured,
all measurements were performed by experimenters blinded to
each culture condition.
Histochemistry and Immunostaining
The axonal fibers of the mouse striatum were examined using a
combined Nissl- and silver-staining method (Bielshowsky staining)
[101]. Double staining for Bielshowsky and Luxol fast blue [26]
was used to demonstrate axons and myelin, respectively. Briefly,
for Bielshowsky staining, frozen brain slides centered at the
ischemic core (coordinates bregma 20.5,0.5 mm) [102] were
placed in 20% silver nitrate in the dark, then ammonium
hydroxide was added to stain the slides until the tissues turned
brown with a gold background and they were then treated with
sodium thiosulfate. Slides were then stained in Luxol fast blue
solution, washed in 95% alcohol, and subsequently placed in
lithium carbonate. Nuclei should be colorless; myelin should be
blue, and axons should appear black. Sections were analyzed with
an optical microscope and pictures were obtained along the IBZ of
the striatum.
Frozen brain sections were incubated with the primary antibody
against synaptophysin (1:100, 60min, RT, Chemicon, MAB5258),
followed with Cy3 labeled secondary antibody. Sections were
observed with a fluorescence microscope and pictures were taken
along the IBZ.
MCID software was used to analyze the integrated density of
labeled axonal fibers and synaptophysin in the IBZ. Five randomly
selected areas along the IBZ were analyzed per animal.
To identify the neuronal apoptosis in the IBZ, double-staining
with an ApopTagH Fluorescein In Situ Apoptosis Detection Kit
(Millipore, Cat # S7110) and with antibody against microtubule-
associated protein 2 (1:200, 4uC overnight, Chemicon, MAB3418)
was employed to stain the frozen brain sections. Sections were
evaluated using a fluorescence microscope and pictures were taken
along the IBZ. The double stained cells in eight randomly selected
areas along the IBZ were measured per section and 3 sections were
taken per animal.
Statistics
Data are expressed as means6SE. The differences between
mean values were evaluated with the two tailed Student’s t-test (for
2 groups) and the analysis of variance (ANOVA, for .2 groups).
All calculations and statistical tests were performed by the
computer programs Microsoft Excel 2000 (Microsoft, Redmond,
WA) or SPSS 11.5 (SPSS, Chicago, IL). P,0.05 was considered
significant for all analyses.
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